Master Transcriptional Regulators in Cancer: Discovery via Reverse Engineering Approaches and Subsequent Validation
Bruce Moran1,2, Arman Rahman1,2, Katja Palonen1,2
1Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Research, UCD Conway Institute, University College Dublin, Dublin, Ireland.
Abstract:
Reverse engineering of transcriptional networks using gene expression data enables identification of genes that underpin the development and progression of different cancers. Methods to this end have been available for over a decade and, with a critical mass of transcriptomic data in the oncology arena having been reached, they are ever more applicable. Extensive and complex networks can be distilled into a small set of key master transcriptional regulators (MTR), genes that are very highly connected and have been shown to be involved in processes of known importance in disease. Interpreting and validating the results of standardized bioinformatic methods is of crucial importance in determining the inherent value of MTRs. In this review, we briefly describe how MTRs are identified and focus on providing an overview of how MTRs can and have been validated for use in clinical decision making in malignant diseases, along with serving as tractable therapeutic targets. Cancer Res; 77(9); 2186-90. ©2017 AACR.
Insights
Master transcriptional regulators (MTRs) identified from gene expression data are key to understanding cancer. Validating these MTRs is crucial for clinical decisions and developing new cancer therapies.
Area of Science:
- Oncology
- Bioinformatics
- Genomics
Background:
- Transcriptional networks are crucial for understanding cancer development and progression.
- Gene expression data analysis offers powerful methods for reverse engineering these networks.
- Master transcriptional regulators (MTRs) are key genes within these networks, highly connected and implicated in disease.
Purpose of the Study:
- To review methods for identifying Master Transcriptional Regulators (MTRs) from gene expression data.
- To provide an overview of MTR validation strategies in oncology.
- To highlight the clinical and therapeutic potential of validated MTRs in malignant diseases.
Main Methods:
- Utilizing gene expression data to computationally identify MTRs within complex transcriptional networks.
- Applying standardized bioinformatic approaches for network analysis and MTR discovery.
- Reviewing established and emerging MTR validation techniques.
Main Results:
- Complex transcriptional networks can be simplified to a core set of MTRs.
- MTRs are highly connected genes central to biological processes in cancer.
- Validation is essential to confirm the clinical relevance and therapeutic tractability of identified MTRs.
Conclusions:
- MTR identification through gene expression analysis is a valuable tool in cancer research.
- Robust validation of MTRs is critical for their translation into clinical practice.
- Validated MTRs hold promise as biomarkers and therapeutic targets for cancer treatment.
More Related Videos
Related Concept Videos
Master Transcription Regulators
Epigenetic Regulation
X-chromosome...
Co-activators and Co-repressors


